The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Someone’s selling and seems determined to drive down the price.
Tedmak.
If we could see where the money is coming from may give us an idea!!
Think they may need to up the offer again!! however they only need 25% more for takeover which is £17m invested. Seems cheap I’d say they’d pay more!!
Daveboy.
Yes I was gutted when Sterritt left and sold a few more when they announced the US strategy.
Confidence and holding back again now though and looking forward to the next 6 months.
This is small cap investing on AIM I guess. A rollercoaster!!
A
Well it’s plain as day the company has a years money left.
My guess is Tim is just about to announce a mega deal with Incanthera, well he has been quiet of late. That will fund the Imm jugernaught through the swings and roundabouts of P3.
What were the P3 trial details again?
A.
HunSen
Very concise due dilligence, thanks for the read.
Company seems to be running well.
My take on raising funds is that its a nececcary evil, better than the company stagnating or worse stumbling at lead candidate blockage without any other potential drugs coming through the testing phases.
As the company looks to place itself at the top of endocrinology there could be some hugh opening markets in adreanal exhaustion from our high stress and gaming societies.
A.
HunSen.
As far as I see the fundraise is part and parcel of an R&D company transition. These funds will enable them to unlock another very important market.
This happens without exception in R&D pharma companies as the big pharma outfits with plenty of cash reserves won’t take on the risk.
It’s never nice to see this dilution but if the company is set up and run well then you should have confidence that the dilution is paying for the next step up in the companies growth.
In the rns they mentioned having meetings with the fda about a spa which will if given cut down the P3 trial time by possibly a couple of years. This is something to look forward to.
Those are my pre coffee thoughts!!
Strange the wife’s always telling me to stop repeating myself.
Not sure Olderandwiser.
I have the UK down as 41000 for this condition.
All things being equal which there not that would be 2-250k.
It’s not a competitive market though.
A.
Not sure Olderandwiser.
I have 41000 written down for UK. All things being equal which there not that would make over 200k. It’s not a competitive market either.
A
Think the imminent news is being priced now.
Eva.
You might want to take a tip from this board and do some DNL due diligence. Get on the train before it leaves the station. Much better equipped train than IMM.
A
If you are like me and concerned shorters will drag the SP down then put a sell order in at a diminutive amount for as long a term as your trading platform allows. Shares that are in the sale process are not available to shorters.
Casapinos.
I think hope your right with the SP. if Shield don’t show a clear road to market this SP will go the same way as every other placing of recent times I’ve seen.
Time to average down or let it cook a while?